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Abstract
Background: Myocardial fibrosis is frequently identified in patients with hypertrophic cardiomyopathy (HCM). The aim 
of this study was to investigate the role of myocardial fibrosis detected by late gadolinium-enhancement (LGE) 
cardiovascular magnetic resonance (CMR) as a potential arrhythmogenic substrate in HCM. We hypothesized that the 
extent of LGE might be associated with the inducibility of ventricular tachyarrhythmias (VT) during programmed 
ventricular stimulation (PVS).
Methods: We evaluated retrospectively LGE CMR of 76 consecutive HCM patients, of which 43 presented with one or 
more risk factors for sudden cardiac death (SCD) and were therefore clinically classified as high-risk patients. Of these 43 
patients, 38 additionally underwent an electrophysiological testing (EP). CMR indices and the extent of LGE, given as 
the % of LV mass with LGE were correlated with the presence of risk factors for SCD and the results of EP.
Results: High-risk patients had a significant higher prevalence of LGE than low-risk patients (29/43 [67%] versus 14/33 
[47%]; p = 0.03). Also the % of LV mass with LGE was significantly higher in high-risk patients than in low-risk patients 
(14% versus 3%, p = 0.001, respectively). Of the 38 high- risk patients, 12 had inducible VT during EP. LV function, 
volumes and mass were comparable in patients with and without inducible VT. However, the % of LV mass with LGE 
was significantly higher in patients with inducible VT compared to those without (22% versus 10%, p = 0.03). The 
prevalence of LGE was, however, comparable between HCM patients with and those without inducible VT (10/12 [83%] 
versus 15/26 [58%]; p = 0.12). In the univariate analysis the % of LV mass with LGE and the septal wall thickness were 
significantly associated with the high-risk group (p = 0.001 and 0.004, respectively). Multivariate analysis demonstrated 
that the extent of LGE was the only independent predictor of the risk group (p = 0.03).
Conclusions: The extent of LGE in HCM patients correlated with risk factors of SCD and the likelihood of inducible VT. 
Furthermore, LGE extent was the only independent predictor of the risk group. This supports the hypothesis that the 
extent of fibrosis may serve as potential arrhythmogenic substrate for the occurrence of VT, especially in patients with 
clinical risk factors for SCD.
Background
Sudden cardiac death (SCD) can be the first and most
devastating clinical manifestation of hypertrophic cardio-
myopathy (HCM). Ventricular tachyarrhythmias (VTs)
seem to be the principal mechanisms of SCD in HCM
patients [1]. Thus, identifying individuals at high risk for
SCD is of paramount importance. Risk stratification of
patients with HCM is mainly based on clinical markers,
such as an unexplained syncope [2], non sustained VT
[3,4], a family history of HCM and SCD [5], and presence
of severe left ventricular hypertrophy [6].
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Although scarred myocardium is an established ana-
tomic and electrophysiological substrate for the occur-
rence of VT and SCD in patients with coronary artery
disease [7,8], its role in HCM is less clear . Evidence for
slowed and fragmented intraventricular conduction as
seen in patients with ischemic heart disease has also been
observed in patients with HCM, and these observations
have been associated with risk for SCD [9-11]. Slowed
conduction in HCM, although attributed to potential
electrophysiological effects of the structural disruption
and myocardial disarray, may simply reflect the substrate
of myocardial scarring as in ischemic heart disease [12].
Late gadolinium-enhanced (LGE) cardiovascular mag-
netic resonance (CMR) allows visualization of myocardial
scarring in HCM [13,14]. Recent studies in patients with
HCM proposed LGE as a predisposing factor for disease
progression and SCD using clinical risk factors as surro-
gates for clinical endpoints [15]. Further studies found
LGE to be most common in HCM patients with VT indi-
cating that LGE may play some role in increasing arrhyth-
mic risk mediated by nonsustained VT [16-18].
The aim of the study was to investigate the role of LGE
as a potential arrhythmogenic substrate in HCM. Thus,
we hypothesized that the extent of LGE is enlarged in
high risk patients for SCD and might be associated with
the inducibility of VTs during programmed ventricular
stimulation (PVS). The results of PVS were therefore
used as surrogate for characterising a potential arrhyth-
mogenic substrate as visualised by LGE CMR and corre-
lated to the CMR findings.
Methods
Study population
A total of 76 patients with HCM (48 males and 26
females; mean age 57 ± 14 years) were evaluated between
February 2003 and December 2009 by CMR at the 1st
Department of Medicine and the Institute of Clinical
Radiology and Nuclear Medicine, University Hospital of
Mannheim, Germany. These patients fulfilled conven-
tional criteria for HCM with LV hypertrophy ≥ 15 mm on
two-dimensional echocardiography in the absence of
another disease that could cause the hypertrophy [19].
The work-up at initial diagnosis included electrocardio-
gram, echocardiography, coronary angiography, left ven-
triculography, 24-h Holter ECG and CMR imaging.
Five clinical risk factors for SCD were used to stratify
the study population in high- and low-risk patients: his-
tory of cardiac arrest, a family history of sudden cardiac
death, unexplained syncope or presyncope, documented
non-sustained ventricular tachycardia and presence of
severe left ventricular hypertrophy ≥ 30 mm [20]. 43 of 76
patients (28 males and 15 females; mean age 56 ± 15
years) presented one or more risk factors for SCD and
were therefore classified as high-risk patients. 38 of these
43 patients additionally underwent a complete electro-
physiological study including programmed ventricular
stimulation (PVS). The remaining 5 patients refused to
undergo an electrophysiological study.
Informed consents for the CMR and the electrophysio-
logical testing protocol were obtained from all subjects.
The performance of this study was consistent with the
standards of the local ethical committee at our institu-
tion.
CMR acquisition
All studies were performed using a 1.5 Tesla whole body
imaging system (Magnetom Sonata, Siemens Medical
Solutions, Erlangen, Germany). A dedicated four-ele-
ment, phased-array body coil was used. Images were
acquired during repeated end-expiratory breath-holds.
Scout images (coronal, sagittal and axial planes) were
obtained for planning of the final double-oblique long-
axis and short-axis views. To evaluate functional parame-
ters, ECG-gated cine images were then acquired using a
segmented steady state free precession (trueFISP)
sequence. Typical scan parameters were: 5 mm slice
thickness with 5 mm interslice gap, temporal resolution
35 ms, repetition time 3.2 ms, echo time 1.2 ms, flip angle
of 60 degrees, and typical in-plane spatial resolution 1.4 ×
1.8 mm2. A stack of 9 to 12 short-axis slices was used for
full coverage of the left and right ventricle.
The LGE images were obtained 10 min after intrave-
nous administration of 0.2 mmol/kg gadolinium-DTPA
(Magnevist, Schering AG, Berlin, Germany). An inver-
sion recovery turbo Fast Low Angle Shot (FLASH)
sequence or a fast multislice single-shot 2D IR true fast
imaging with steady-state precession sequence were used
to obtain images at the same position as the long- and
short-axis cines in end-diastole (Figure 1) [21,22]. The
inversion time was adjusted per patient to optimally null
signal from normal myocardium (typically 250 to 300
ms). Total acquisition time averaged 40 minutes.
Image analysis and determination of ventricular and atrial 
parameters
CMR images were analysed both qualitatively and quanti-
tatively by two experienced investigators blinded to the
electrophysiological findings. LV end-diastolic volumes,
LV end-systolic volumes, LV stroke volume and LV ejec-
tion fraction were assessed off-line from the serial short-
axis trueFISP cine loops using dedicated commercially
available software (ARGUS, Siemens, Erlangen, Ger-
many). In addition to volumetric measurements, one-
dimensional measurements of LV end diastolic dimen-
sions, posterior wall thickness and maximum interven-Fluechter et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:30
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tricular septum wall thickness were measured from end
diastolic short-axis views.
The LGE was assessed visually, and the LGE mass was
measured by manual planimetry on all short-axis slices by
2 observers blinded to all patient details (SF; TP) (Figure
1). Summing the LGE mass of all slices yielded the total
mass of LGE. The extent of LGE was then expressed as a
percentage of the total LV mass (the % of LV mass with
LGE).
Programmed ventricular stimulation
43 of the 76 patients presented one or more risk factors
for SCD. 38 of these 43 high-risk patients underwent a
complete electrophysiological study including pro-
grammed ventricular stimulation. Antiarrhythmic drugs
were discontinued for at least five half-lives before elec-
trophysiological study. Two bipolar or quadripolar cathe-
ters were introduced percutaneously through the right or
left femoral vein and positioned at the high right atrium
and the right ventricular apex under fluoroscopic guid-
ance. PVS was performed using a Biotronik UHS-20
stimulator (Biotronik GmbH & Co. KG). Pulses of 1.9 ms
in duration were applied at twice diastolic threshold.
Electrophysiological study protocol
Assessment of sinus node recovery time, atrial and atrio-
ventricular node refractoriness was performed with a
conventional stimulation protocol. PVS was performed
with up to three extrastimuli at three different driving
cycle lengths (500 ms, 430 ms, and 370 ms) at the right
ventricular apex and the right ventricular outflow tract
until refractoriness. VT/VF were defined as sustained
when the duration exceeded 30 s or required cardiover-
sion for hemodynamic collapse.
Statistical analysis
All data are presented as a mean ± standard deviation.
For comparing left and right ventricular parameters and
LGE-extent in different patients groups an unpaired, 2-
tailed student's t-test was used. A Chi-square test was
used to evaluate if the presence of LGE, risk factors for
SCD and clinical symptoms were different between dif-
ferent patients groups.
Multivariate analysis was performed with logistic
regression analysis using block entry of the following
variables: extent of LGE and septal wall thickness to eval-
uate if these variables were independent predictors of the
risk group in HCM patients, provided to have a p < 0.05
in univariate analysis.
All results were considered statistically significant
when p < 0.05. Analyses were performed with Statistical
Package for Social Sciences (SPSS for windows 14.0, Chi-
cago, IL, USA).
Results
There were no statistically significant differences regard-
ing sex and age between patients at high- and low- risk
for SCD (Table 1). Table 1 also shows the values for all LV
parameters for patients at high- and low-risk for SCD
measured by CMR and the clinical characteristics.
Besides a significantly thickened septum wall in high risk
patients, there were no statistically significant differences
in LV-function and volumes between high- and low-risk
patients. High-risk patients showed a significantly higher
prevalence of LGE than low-risk patients (29/43 [67%]
versus 14/33 [47%]; X2 = 4.69, p = 0.03). Additionally, the
% of LV mass with LGE was significantly higher in high-
than in low-risk patients (14% vs. 3% in low-risk patients;
p = 0.01) (Table 1).
In T able 2 patients at high risk for SCD were further
subdivided in patients with and without inducible ven-
tricular tachyarrhythmias during PVS. There were no sta-
tistically significant differences in LV-function and
volumes between patients with and without inducible
tachyarrhythmias. Patients with inducible ventricular
tachycardias showed a higher prevalence of LGE than
patients without (10/12 = 83% versus 15/26 = 58%), but
this difference did not reach statistical significance (chi
Figure 1 Late gadolinium enhancement (LGE) in a short axis view 
of a patient with hypertrophic cardiomyopathy: Endocardial 
(......) and epicardial (-----) contours. % of LV mass with LGE assessed 
by visual planimetry (thick line).Fluechter et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:30
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square test: X2 = 2.34, p = 0.12). The % of LV mass with
LGE, however, was significantly higher in patients with
inducible ventricular tachyarrhythmias compared to
those without (22% versus 10%, p = 0.03).
Clinical characteristics and risk factors of patients at
high risk for SCD are presented in table 3. There were no
statistical differences concerning the incidence of any of
the listed criteria between patients with inducible VT/VF
and patients without. However, 7 out of 12 patients with
inducible tachyarrhythmias had two or more risk factors
f o r  SCD ,  c o m p a r ed  t o  o n l y  5  i n  t h e  gr o u p  o f  pa t i e n ts
without inducible VT/VF (p = 0.04).
In the univariate analysis the % of LV mass with LGE
and the septal wall thickness were significantly associated
with the high-risk group in HCM patients (p = 0.001 and
0.004, respectively). The multivariate logistic regression
analysis, a model using these both parameters to predict
the high risk group in HCM patients revealed that only
the % of LV mass with LGE was independently associated
with the high risk group in HCM patients (p = 0.03).
PVS results in high-risk patients
Sustained ventricular tachyarrhythmias were inducible in
12 of 38 patients (32%). Polymorphic VT and VF were
Table 1: CMR parameters and clinical characteristics of patients at high- and low-risk for sudden cardiac death
Patients at
High risk
Patients at
Low-risk
p-values
n4 3 3 3
male gender 28 20 0.50
Age 57 ± 14 61 ± 10 0.29
CMR parameters
EF (%) 57 ± 4 62 ± 10 0.09
EDM (g) 195 ± 58 181 ± 76 0.36
EDV (ml) 156 ± 53 139 ± 42 0.14
ESV (ml) 67 ± 32 54 ± 28 0.07
SV (ml) 88 ± 30 84 ± 28 0.58
LVEDD (mm) 50 ± 7 49 ± 7 0.54
SWT (mm) 20 ± 5 17 ± 4 0.004
PWT (mm) 10 ± 3 10 ± 2 0.91
RVEDD (mm) 43 ± 6 42 ± 7 0.42
RVESD (mm) 28 ± 6 28 ± 7 0.76
Presence
of LGE
29/43
(67%)
14/33
(47%)
0.03
% of LV mass with LGE 14% 3% 0.001
Clinical characteristics
Dyspnea 11 4 0.14
Chest pain 13 5 0.12
Atrial fibrillation 18 3 0.26
HCM with obstruction 25 10 0.06
Diabetes 4 5 0.35
Hypertension 25 19 0.49
Hyperlipidemia 10 13 0.13
EDM = enddiastolic mass; EDV = enddiastolic volume; EF = ejection fraction; ESV = endsystolic volume; LGE = Late gadolinium enhancement; 
LV = left ventricular; Presence of LGE = Number of patients in whom LGE was detectable; LVEDD = left ventricular enddiastolic diameter; PWT 
= posterior-wall-thickness; RVEDD/RVESD = right ventricular enddiastolic/enddiastolic diameter; SV = stroke volume; SWT = Septal-wall-
thickness; (Mean value ± standard deviation).Fluechter et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:30
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inducible in 7 and 5 patients, respectively (Table 4). In 26
patients no sustained tachycardia was inducible.
Discussion
The present study demonstrates with state-of-the-art
CMR that HCM patients at high risk for SCD show a sig-
nificantly higher prevalence and % of LV mass with LGE
c o m p a r e d  t o  l o w - r i s k  p a t i e n t s .  M o r e o v e r  h i g h - r i s k
patients with inducible ventricular tachyarrhythmias dur-
ing PVS displayed significantly more LGE compared to
patients without inducible tachyarrhythmias. However,
the presence of LGE was not related to the inducibility of
ventricular tachyarrhythmias. Additionally, LGE extent
was the only independent predictor of the risk group.
These findings provide further evidence in support of the
hypothesis that myocardial fibrosis is an important
arrhythmogenic substrate in patients with HCM.
The histological basis for LGE in patients with HCM is
currently believed to be increased collagen deposition
[13]. Focal areas of fibrosis caused by myocardial scarring
or interstitial fibrosis may serve as anatomical substrate
for the occurrence of ventricular tachyarrhythmias.
Moon et al found a relation between the extent of LGE
and clinical risk factors for SCD in patients with HCM
[15]. This observation is in line with our results, where
high risk patients presented a significantly higher % of LV
mass with LGE than patient without risk factors for SCD.
In our retrospective study the results of PVS were addi-
tionally used to further characterise patients at high risk
for SCD. In literature the value of electrophysiological
testing in HCM is discussed controversially so that cur-
rent guidelines do not recommend electrophysiological
testing in risk stratification of HCM [23]. Nevertheless
Fananapazir et al. could show that patients with inducible
VT had a poorer prognosis than those without inducible
arrhythmias [24].
Our results show a correlation between the inducibility
of ventricular tachyarrhythmias and the extent of LGE in
patients with HCM. The findings of this study are consis-
tent with recent reports of the correlation between risk of
arrhythmia and the presence and morphology of scar in
other patients groups such as those with ischemic or non
Table 2: CMR parameters of high risk patients with and without inducible VT/VF during EP
Patients with
inducible VT/VF (*)
Patients without
inducible VT/VF (*)
p-values
n 12 26
male gender 71 7 0.45
age 60 ± 11 54 ± 16 0.34
EF (%) 58 ± 13 59 ± 10 0.81
EDM (g) 202 ± 58 195 ± 59 0.32
EDV (ml) 169 ± 60 150 ± 48 0.32
ESV (ml) 75 ± 45 63 ± 26 0.31
SV (ml) 94 ± 29 85 ± 30 0.41
LVEDD (mm) 50 ± 9 51 ± 7 0.85
SWT (mm) 22 ± 4 19 ± 5 0.13
PWT (mm) 10 ± 3 11 ± 4 0.34
RVEDD (mm) 44 ± 5 43 ± 7 0.63
RVSD (mm) 27 ± 7 28 ± 6 0.45
Presence
of LGE
10/12
(83%)
15/26
(58%)
0.12
% of LV mass with LGE 22% 10% 0.03
(*) 38 of 43 High risk patients underwent EP-testing; EDM = enddiastolic mass; EDV = enddiastolic volume; EF = left ventricular ejection 
fraction; ESV = endsystolic volume; LGE = Late gadolinium enhancement; Extent of LGE(%) = Extent of LGE expressed as a percentage of total 
myocardium; Presence of LGE = Number of patients in whom LGE was detectable (irrespective of extent); Segments with LGE = Number of 
segments according to the AHA 17-segments system that show LGE; LVEDD = left ventricular enddiastolic diameter; PWT = posterior-wall-
thickness; RVEDD = right ventricular enddiastolic diameter; RVESD = right ventricular endsystolic diameter; SV = stroke volume; SWT = Septal-
wall-thickness; (Mean value ± standard deviation).Fluechter et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:30
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ischemic cardiomyopathy: Schmidt et al. demonstrated in
a high-risk population of patients with prior myocardial
infarction and LV dysfunction, that tissue heterogeneity
detected by LGE-CMR correlates with an enhanced sus-
ceptibility to ventricular arrhythmia during EP or device
testing [25]. Bello et al. could point out that in patients
with known coronary artery disease, infarct surface area
and mass defined by LGE-CMR were better identifiers of
inducible monomorphic VT during electrophysiological
testing than LV ejection fraction alone [26]. Additionally,
Nazarian and al. found out, that the distribution of scar
identified by CMR is also predictive of inducible VT in
patients with nonischemic cardiomyopathy [27].
Teraoka et al. correlated the extent of LGE with the
occurrence of ventricular tachyarrhythmias in patients
with HCM. The group with VT/VF showed significantly
more often LGE (p < 0.05) and the areas of LGE were sig-
nificantly larger (p = 0.03) [16]. In this context, Varnava et
al. examined the pathologic findings in 75 patients with
HCM in relation to morphology, clinical features, and
patient outcome. Myocardial fibrosis was markedly
increased in patients who had documented nonsustained
VT or a high risk fractionation study, suggesting that
fibrosis rather than disarray is the anatomic substrate for
sudden death [28]. Since LGE can non-invasively identify
fibrotic tissue in patients with HCM, the findings of Var-
nava et al. underline the potential prognostic value of
CMR imaging in patients with HCM.
Accordingly, Adabag and colleagues recently found that
premature ventricular contractions, couplets and nonsus-
tained ventricular tachycardia on 24-h ambulatory Holter
electrocardiograms were more common in patients with
HCM and LGE than in patients without. Within the
group of LGE the risk of ventricular arrhythmias was not
correlated to the extent of LGE [17]. In our present analy-
s i s ,  t h e  m e r e  p r e s e n c e  o f  L G E  w a s  n o t  r e l a t e d  t o  t h e
inducibility of ventricular tachyarrhythmias. The lack of
association between presence of LGE and inducibility of
ventricular tachyarrhythmias was unexpected. There was
a distinct trend toward a higher prevalence of LGE in
patients with inducible ventricular tachyarhythmias, but
this difference did not reach statistical significance, since
the study seems underpowered for this comparison. Only
the extent of LGE correlated significantly with the induc-
ibility of ventricular tachyarrhythmias. One further pos-
sible explanation for the differences between the two
studies might be owing to the different composition of
the cohorts. Our patients were older (mean-age of 57 ±
14 years vs. 41 ± 16 years) and showed a higher preva-
lence of LGE (57% vs 41%). Additionally, inducibility of
Table 3: Risk factors for SCD and clinical characteristics of high risk patients with and without inducible ventricular 
tachyarrhythmias.
Inducible VT/VF (*) No-inducible VT/VF (*) p-values
n1 2 2 6
Risk factors for sudden cardiac death
Aborted sudden death 1 0 0.14
Family history of SCD 2 3 0.45
Syncope or presyncope 8 17 0.49
Documented nsVT 6 9 0.31
Wall thickness > 30 mm 2 1 0.16
2 or more risk factors 7 5 0.04
Clinical characteristics and symptoms
Dyspnea 3 6 0.49
Chest pain 5 7 0.30
Palpitations 3 6 0.49
Atrial fibrillation 6 10 0.38
HCM with obstruction 7 15 0.49
Diabetes 2 1 0.16
Hypertension 8 15 0.42
Hyperlipidemia 3 5 0.45
(*) 38 of 43 High risk patients underwent EP-testing; nsVT = non sustained ventricular tachycardia; SCD = sudden cardiac death; VF Ventricular 
Fibrillation; VT = Ventricular Tachycardia;Fluechter et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:30
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ventricular tachyarrhythmias is a different denominator
or clinical endpoint than PVC, or NSVT and therefore
can not be directly compared.
Study limitations
We performed a retrospective observational study with a
rather small sample size. Additionally, only patients who
w e r e  c l i n i c a l l y  c l a s s i f i e d  a s  h i g h  r i s k  p a t i e n t s  f o r  S C D
were examined by EP. Therefore this study population
contains a selection of symptomatic patients which does
not reflect the broad spectrum of patients with HCM.
At present there is no general consensus on the strategy
how to exactly define the extent of LGE in HCM. In our
study we analyzed LGE-extent by visual assessment.
According to our own experience and to recent studies by
Adabag et al. and Bondarenko et al. visual estimation
yields comparable results to assessment with 5- or 6-SD
threshold techniques whereas strategies thresholding at
2-SD may result in an overestimation of LGE-extent
[17,29].
Conclusions
HCM patients with clinical risk factors for SCD show a
significantly higher prevalence and larger extent of LGE
compared to low-risk patients. Moreover the likelihood
of inducible ventricular tachyarrhythmias increases with
the extent of LGE in HCM patients at high risk for SCD.
Additionally, LGE extent was the only independent pre-
dictor of the risk group. These findings provide further
evidence in support of the hypothesis that the extent of
fibrosis potentiates the arrhythmogeneity in HCM and
underline a potential predictive value of LGE CMR in
patients with HCM as an adjuvant to current risk stratifi-
cation protocols.
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